Attached files
| file | filename |
|---|---|
| 8-K - FORM 8-K - Shire plc | dp28903_8k.htm |
Exhibit 99.01
|
Press Release
|
 |
|
www.shire.com
|
|
Director/PDMR Share Dealings
February 22, 2012 – Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company announces the following dealings by Persons Discharging Managerial Responsibility (“PDMRs”) in Shire plc ordinary shares of 5p (“Shares”).
Release of Performance Share Awards (“PSA Awards”)
In accordance with the rules of the Portfolio Share Plan (“PSP”), the following Shares were released on February 20, 2012 in connection with PSA Awards granted in 2009 under Part B of the PSP. The Company was notified on February 21, 2012 that sufficient Shares were sold on February 20, 2012 to satisfy the personal tax liabilities of each PDMR.
|
No of Shares
released
|
No of Shares
sold
|
Average sale
price
|
|
|
Angus Russell1
|
225,582
|
77,719
|
£22.564711
|
|
Graham Hetherington1
|
76,318
|
40,179
|
£22.538221
|
|
Tatjana May
|
30,527
|
16,078
|
£22.538221
|
1 The PSA Awards granted in 2009 to Angus Russell and Graham Hetherington were subject to performance criteria measured over the performance period 2009 to 2011. Based on the performance criteria, 100% of the PSA Awards vested.
Exercise of Stock Appreciation Right Awards (“SAR Awards”)
The Company was notified on February 21, 2012 and on February 22, 2012 of the exercise of the following SAR Awards which were granted under Part A of the PSP.
|
No of
Shares
exercised
|
Exercise
price
|
No of
Shares
received
|
No of
Shares
sold
|
Average
sale price
|
|
|
Angus Russell 1
|
108,721
|
£8.13
|
69,953
|
24,234
|
£22.557733
|
|
Graham Hetherington 2
|
100,000
|
£8.83
|
61,135
|
61,135
|
£22.571881
|
|
Tatjana May 3
|
40,000
|
£8.83
|
24,161
|
24,161
|
£22.30140
|
1 The SAR Award granted in 2008 to Mr Russell was subject to performance criteria measured over the performance period 2008 to 2010. Based on the performance criteria, 88% of the SAR Award vested. The SAR Award was exercised on February 20, 2012. Mr Russell sold sufficient Shares to satisfy his personal tax liabilities.
² The SAR Award granted in 2009 to Mr Hetherington was subject to performance criteria measured over the performance period 2009 to 2011. Based on the performance criteria, 100% of the SAR Award vested. The SAR Award was exercised on February 20, 2012. Mr Hetherington sold all his Shares, part of which were to satisfy his personal tax liabilities.
3 Ms May exercised her SAR Award on February 22, 2012 and sold all the resulting Shares, part of which were to satisfy her personal tax liabilities.
Sale of Shares
The Company was notified on February 21, 2012 of the sale by Angus Russell, on February 20, 2012, of 131,330 Shares at an average sale price of £22.564.
In addition, the Company was notified on February 21, 2012 of the sale by Graham Hetherington, on the same day, of 20,000 Shares at an average sale price of £22.300615.
Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX
Resulting Interests
After the above transactions, Angus Russell and Graham Hetherington hold the following interests.
|
Type of
security
|
No of
Shares/ADSs
|
SAR
Awards/
Options
|
PSA
Awards
|
Restricted
Shares/ADSs
|
|
|
Angus Russell
|
ADSs 1
|
-
|
168,742
|
121,292
|
11,415
|
|
Shares
|
193,582
|
295,580
|
-
|
37,814
|
|
|
Graham Hetherington
|
Shares
|
34,004
|
217,687
|
159,633
|
28,080
|
1 One ADS is equal to three Shares.
This notification relates to disclosures made in accordance with 3.1.4(R)(1)(a) of the Disclosure and Transparency Rules.
Tony Guthrie
Deputy Company Secretary
For further information please contact:
|
Investor Relations
|
Eric Rojas (erojas@shire.com)
|
+1 781 482 0999
|
|
Sarah Elton-Farr (seltonfarr@shire.com)
|
+44 1256 894157
|
Notes to editors
SHIRE PLC
Shire’s strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder, human genetic therapies, gastrointestinal diseases and regenerative medicine as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire’s in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.
For further information on Shire, please visit the Company’s website: www.shire.com.